Furthermore, pretreatment with STAR2 before allogeneic hematopoietic stem cell transplantation (allo-HCT) markedly prolonged the survival and decreased the severity of GVHD, in TNFR2- and Treg-dependent manner. The gene discussed is TNFRSF1B; the disease is graft versus host disease.